The impact of pharmacist interventions on osteoporosis management: a systematic review

M N Elias, A M Burden, S M Cadarette, M N Elias, A M Burden, S M Cadarette

Abstract

We completed a systematic review of the literature to examine the impact of pharmacist interventions in improving osteoporosis management. Results from randomized controlled trials suggest that pharmacist interventions may improve bone mineral density testing and calcium intake among patients at high risk for osteoporosis.

Introduction: Pharmacists play a key role in many healthcare systems by helping patients manage chronic diseases. We completed a systematic review of the literature to identify randomized controlled trials (RCTs) that have examined the impact of pharmacy interventions in narrowing two gaps in osteoporosis management: identifying at-risk individuals and improving adherence to therapy.

Methods: We searched the electronic databases of EMBASE, HealthStar, International Pharmaceutical Abstracts, MEDLINE, and PubMed from database development to April 2010, examined grey literature, and completed manual searches of reference lists to identify English-language research that examined osteoporosis management interventions within pharmacy practice. Results from RCTs were abstracted and assessed for bias.

Results: We identified 25 studies that examined pharmacist interventions in osteoporosis management: 16 cohort, 5 cross-sectional, 1 historical/ecological control, and 3 RCTs. RCT interventions included osteoporosis educational and counseling programs, screening by pharmacists based on risk factor assessment or bone mineral density testing, and physician contact or recommendations for patients to follow-up with a general practitioner. Results from the three RCTs suggest that pharmacist interventions may improve bone mineral density testing (targeted screening) and calcium intake among patients at high risk for osteoporosis. However, two of the three RCTs had high risk of bias, and no study examined the impact of pharmacist intervention on osteoporosis treatment adherence.

Conclusions: Data support the potential role for pharmacists to help reduce gaps in osteoporosis management through improved identification of high-risk patients. More research is needed to examine pharmacist interventions on osteoporosis treatment adherence.

Figures

Fig. 1
Fig. 1
Flow chart of literature search strategy. IPA International Pharmaceutical Abstracts. *no grey literature identified from our primary search (Appendix Table 5)

References

    1. Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int. 2004;15:767–778. doi: 10.1007/s00198-004-1675-5.
    1. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18:1023–1031. doi: 10.1007/s00198-006-0322-8.
    1. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82:1493–1501. doi: 10.4065/82.12.1493.
    1. Little EA, Eccles MP. A systematic review of the effectiveness of interventions to improve post-fracture investigation and management of patients at risk of osteoporosis. Implement Sci. 2010;5:80–97. doi: 10.1186/1748-5908-5-80.
    1. Lai P, Chua SS, Chan SP. A systematic review of interventions by healthcare professionals on community-dwelling postmenopausal women with osteoporosis. Osteoporos Int. 2010;21:1637–1656. doi: 10.1007/s00198-010-1199-0.
    1. O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev. 2006;18:CD005326.
    1. Alberani V, De Castro PP, Mazza AM. The use of grey literature in health sciences: a preliminary survey. Bull Med Libr Assoc. 1990;78:358–363.
    1. Charrois T, Durec T, Tsuyuki RT. Systematic reviews of pharmacy practice research: methodologic issues in searching, evaluating, interpreting, and disseminating results. Ann Pharmacother. 2009;43:118–122. doi: 10.1345/aph.1L302.
    1. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ. 2001;323:42–46. doi: 10.1136/bmj.323.7303.42.
    1. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147:W163–W194.
    1. Taylor SJ, Crockett JA, McLeod LJ (2004) An integrated service, initiated by community pharmacists, for the prevention of osteoporosis. In Australian Government Department of Health and Ageing (ed)
    1. Cerulli J, Zeolla MM. Impact and feasibility of a community pharmacy bone mineral density screening and education program. J Am Pharm Assoc (2003) 2004;44:161–167. doi: 10.1331/154434504773062618.
    1. Elliott ME, Meek PD, Kanous NL, et al. Pharmacy-based bone mass measurement to assess osteoporosis risk. Ann Pharmacother. 2002;36:571–577. doi: 10.1345/aph.1A299.
    1. Goode JV, Swiger K, Bluml BM. Regional osteoporosis screening, referral, and monitoring program in community pharmacies: findings from Project ImPACT: Osteoporosis. J Am Pharm Assoc (2003) 2004;44:152–160. doi: 10.1331/154434504773062609.
    1. Hall LN, Shrader SP, Ragucci KR. Evaluation of compliance with osteoporosis treatment guidelines after initiation of a pharmacist-run osteoporosis service at a family medicine clinic. Ann Pharmacother. 2009;43:1781–1786. doi: 10.1345/aph.1M366.
    1. Ho C, Cranney A, Campbell A. Measuring the impact of pharmacist intervention: results of patient education about osteoporosis after fragility fracture. Can J Hosp Pharm. 2006;59:184–193.
    1. Johnson JF, Koenigsfeld C, Hughell L, Parsa RA, Bravard S. Bone health screening, education, and referral project in northwest Iowa: creating a model for community pharmacies. J Am Pharm Assoc (2003) 2008;48:379–387. doi: 10.1331/JAPhA.2008.07026.
    1. Law AV, Shapiro K. Impact of a community pharmacist-directed clinic in improving screening and awareness of osteoporosis. J Eval Clin Pract. 2005;11:247–255. doi: 10.1111/j.1365-2753.2005.00531.x.
    1. MacLaughlin EJ, MacLaughlin AA, Snella KA, et al. Osteoporosis screening and education in community pharmacies using a team approach. Pharmacotherapy. 2005;25:379–386. doi: 10.1592/phco.25.3.379.61604.
    1. Nadrash TA, Plushner SL, Delate T. Clinical pharmacists' role in improving osteoporosis treatment rates among elderly patients with untreated atraumatic fractures. Ann Pharmacother. 2008;42:334–340. doi: 10.1345/aph.1K541.
    1. Naunton M, Peterson GM, Jones G. Pharmacist-provided quantitative ultrasound screening for rural women at risk of osteoporosis. Ann Pharmacother. 2006;40:38–44.
    1. Newman ED, Hanus P. Improved bone health behavior using community pharmacists as educators: the Geisinger health system community pharmacist osteoporosis education program. Dis Manag Health Outcomes. 2001;9:329–335. doi: 10.2165/00115677-200109060-00004.
    1. Riley K, Martin J, Wazny LD. Impact of pharmacist intervention on osteoporosis treatment after fragility fracture: positive effect of pharmacist information program shown in pilot study. Can Pharm J. 2005;138:37–43.
    1. Siow JY, Lai PS, Chua SS, Chan SP. The impact of pharmacist intervention on the use of activated vitamin D in a tertiary referral hospital in Malaysia. Int J Pharm Pract. 2009;17:305–311. doi: 10.1211/ijpp.17.05.0008.
    1. Stroup JS, Rivers SM, Abu-Baker AM, et al. Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic. Pharmacotherapy. 2007;27:779–788. doi: 10.1592/phco.27.6.779.
    1. Summers KM, Brock TP. Impact of pharmacist-led community bone mineral density screenings. Ann Pharmacother. 2005;39:243–248. doi: 10.1345/aph.1E321.
    1. Peters S, Singla D, Raney E. Impact of pharmacist-provided osteoporosis education and screening in the workplace. J Am Pharm Assoc (2003) 2006;46:216–218. doi: 10.1331/154434506776180603.
    1. Chaiyakunapruk N, Laowakul A, Karnchanarat S, Pikulthong N, Ongphiphadhanakul B. Community pharmacy-based implementation and evaluation of an osteoporosis self-assessment tool for Asians. J Am Pharm Assoc (2003) 2006;46:391–396. doi: 10.1331/154434506777069624.
    1. Gloth FM, Simonson W. Osteoporosis is underdiagnosed in skilled nursing facilities: a large-scale heel BMD screening study. J Am Med Dir Assoc. 2008;9:190–193. doi: 10.1016/j.jamda.2007.12.003.
    1. Liu Y, Nevins JC, Carruthers KM, et al. Osteoporosis risk screening for women in a community pharmacy. J Am Pharm Assoc (2003) 2007;47:521–526. doi: 10.1331/JAPhA.2007.05107.
    1. Wilcock M, MacMahon D, Woolf A. Use of medicines that influence falls or fractures in a residential home setting. Pharm World Sci. 2005;27:220–222. doi: 10.1007/s11096-004-3707-9.
    1. Lata PF, Binkley NC, Elliott ME. Acceptability of pharmacy-based bone density measurement by women and primary healthcare providers. Menopause. 2002;9:449–455. doi: 10.1097/00042192-200211000-00011.
    1. Naunton M, Peterson GM, Jones G, Griffin GM, Bleasel MD. Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis. J Rheumatol. 2004;31:550–556.
    1. Crockett JA, Taylor SJ, McLeod LJ. Patient responses to an integrated service, initiated by community pharmacists, for the prevention of osteoporosis. Int J Pharm Pract. 2008;16:65–72. doi: 10.1211/ijpp.16.2.0003.
    1. McDonough RP, Doucette WR, Kumbera P, Klepser DG. An evaluation of managing and educating patients on the risk of glucocorticoid-induced osteoporosis. Value Health. 2005;8:24–31. doi: 10.1111/j.1524-4733.2005.04007.x.
    1. Yuksel N, Majumdar SR, Biggs C, Tsuyuki RT. Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial. Osteoporos Int. 2010;21:391–398. doi: 10.1007/s00198-009-0977-z.
    1. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–543.
    1. Jones EJ, Mackinnon NJ, Tsuyuki RT. Pharmaceutical care in community pharmacies: practice and research in Canada. Ann Pharmacother. 2005;39:1527–1533. doi: 10.1345/aph.1E456.
    1. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother. 2007;41:1569–1582. doi: 10.1345/aph.1K151.
    1. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother. 2007;41:1770–1781. doi: 10.1345/aph.1K311.
    1. Machado M, Nassor N, Bajcar JM, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother. 2008;42:1195–1207. doi: 10.1345/aph.1K618.
    1. Barr RJ, Stewart A, Torgerson DJ, Reid DM. Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk. Osteoporos Int. 2010;21:561–568. doi: 10.1007/s00198-009-1007-x.
    1. Cook RB, Collins D, Tucker J, Zioupos P. Comparison of questionnaire and quantitative ultrasound techniques as screening tools for DXA. Osteoporos Int. 2005;16:1565–1575. doi: 10.1007/s00198-005-1864-x.
    1. Fan E, Laupacis A, Pronovost PJ, Guyatt GH, Needham DM. How to use an article about quality improvement. JAMA. 2010;304:2279–2287. doi: 10.1001/jama.2010.1692.
    1. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377–384. doi: 10.1136/jech.52.6.377.
    1. Higgins J, Green S (eds) (2009) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. Available from
    1. Cadarette SM, Burden AM. Measuring and improving adherence to osteoporosis pharmacotherapy. Curr Opin Rheumatol. 2010;22:397–403. doi: 10.1097/BOR.0b013e32833ac7fe.
    1. Gleeson T, Iversen MD, Avorn J, et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int. 2009;20:2127–2134. doi: 10.1007/s00198-009-0976-0.
    1. Cadarette SM, Beaton DE, Gignac MAM, et al. Minimal error in self-report of having had DXA, but self-report of its results was poor. J Clin Epidemiol. 2007;60:1306–1311. doi: 10.1016/j.jclinepi.2007.02.010.
    1. Cadarette SM, Jaglal SB, Raman-Wilms L, Beaton DE, Paterson JM. Osteoporosis quality indicators using healthcare utilization data. Osteoporos Int. 2011;22:1335–1342. doi: 10.1007/s00198-010-1329-8.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner